Efficacy and impact on cancer treatment of SARS-CoV-2 vaccination for breast cancer patients: multi-center prospective observational study
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000045527
- Lead Sponsor
- agoya City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of COVID-19 by the date of study enrollment 2) Patients with inappropriate SARS-CoV-2 vaccination 3) Other patients deemed unsuitable as subjects by the principal investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Titer of antibody against SARS-CoV-2 S protein in serum after 4 weeks from vaccination
- Secondary Outcome Measures
Name Time Method Effect on treatment related vaccination
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SARS-CoV-2 vaccination to improved outcomes in breast cancer patients?
How does SARS-CoV-2 vaccination impact treatment adherence and disease progression in breast cancer compared to no vaccination?
Which biomarkers predict SARS-CoV-2 vaccine efficacy in JPRN-UMIN000045527 breast cancer subtypes like HER2-positive or triple-negative?
What are the safety profiles of SARS-CoV-2 vaccines in breast cancer patients undergoing chemotherapy or immunotherapy?
Are there synergistic effects between SARS-CoV-2 vaccination and PD-1/PD-L1 inhibitors in breast cancer management?